Summing up, our findings of TACSTD2 DNA methylation alterations in RCC and the corresponding in silico analyses including KIRC data set (methylation, mRNA expression) as well as proteinatlas.org data (protein expression) could point to an association of loss of TACSTD2 expression with a more aggressive biological phenotype of RCC. This evidence concerns the gene TACSTD2 and renal cell carcinoma.